Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating Overview
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Acadia Pharmaceuticals (ACAD) PT Lowered to $39 at Mizuho, 'Daybue Seasonality Trend May Raise Concerns'
February 28, 2024 6:15 AM ESTMizuho Securities analyst Uy Ear lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $39.00 (from $40.00) while maintaining a Buy rating.
The analyst comments "With investor focus on the Daybue launch, ACAD will likely trade down today. We would buy on weakness. Investors... More
Acadia Pharma (ACAD) Misses Q4 EPS by 1c
February 27, 2024 4:24 PM ESTAcadia Pharma (NASDAQ: ACAD) reported Q4 EPS of $0.28, $0.01 worse than the analyst estimate of $0.29. Revenue for the quarter came in at $231 million versus the consensus estimate of $223.77 million.
Full Year 2024 Financial Guidance
DAYBUE net product sales in the range of $370 to $420... More